CN1887303A - Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver - Google Patents
Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver Download PDFInfo
- Publication number
- CN1887303A CN1887303A CNA200510097344XA CN200510097344A CN1887303A CN 1887303 A CN1887303 A CN 1887303A CN A200510097344X A CNA200510097344X A CN A200510097344XA CN 200510097344 A CN200510097344 A CN 200510097344A CN 1887303 A CN1887303 A CN 1887303A
- Authority
- CN
- China
- Prior art keywords
- alcohol extract
- fatty liver
- herb
- group
- alcoholic fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 239000000284 extract Substances 0.000 title claims abstract description 51
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 22
- 235000010662 Bidens pilosa Nutrition 0.000 title claims description 44
- 241000143476 Bidens Species 0.000 title claims description 43
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 15
- 208000004930 Fatty Liver Diseases 0.000 abstract description 9
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 9
- 208000010706 fatty liver disease Diseases 0.000 abstract description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 8
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 5
- 206010070863 Toxicity to various agents Diseases 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 235000009200 high fat diet Nutrition 0.000 abstract description 2
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000017074 necrotic cell death Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 229930003944 flavone Natural products 0.000 description 8
- 235000011949 flavones Nutrition 0.000 description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 8
- 235000005687 corn oil Nutrition 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- -1 ketone alkene Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000104272 Bidens pilosa Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001197 polyacetylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 241000842328 Bidens bipinnata Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- RTAZJHSWWRKIOX-UHFFFAOYSA-N Okanin Natural products Oc1ccc(C=CC(=O)c2c(O)ccc(O)c2O)c(O)c1O RTAZJHSWWRKIOX-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- GSBNFGRTUCCBTK-DAFODLJHSA-N okanin Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C(O)=C1O GSBNFGRTUCCBTK-DAFODLJHSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GVSPXQVUXHMUMA-MDWZMJQESA-N (e)-3-(3,5-ditert-butyl-4-hydroxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)\C=C\C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 GVSPXQVUXHMUMA-MDWZMJQESA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241000422920 Cordyceps gunnii Species 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- PNIFOHGQPKXLJE-UHFFFAOYSA-N Maritimetin Natural products C1=C(O)C(O)=CC=C1C=C1C(=O)C(C=CC(O)=C2O)=C2O1 PNIFOHGQPKXLJE-UHFFFAOYSA-N 0.000 description 1
- 241001077898 Melanthera Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229930015036 aurone Natural products 0.000 description 1
- 150000001530 aurones Chemical class 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000004073 flavone group Chemical group 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- SYRURBPRFQUYQS-RHEJLWEFSA-N maritimein Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C(=O)\C(O2)=C\C=3C=C(O)C(O)=CC=3)C2=C1O SYRURBPRFQUYQS-RHEJLWEFSA-N 0.000 description 1
- HKPKOABKPSVNGM-UHFFFAOYSA-N maritimein Natural products OCC1OC(Oc2ccc3C=C(OCc3c2O)C(=O)c4ccc(O)c(O)c4)C(O)C(O)C1O HKPKOABKPSVNGM-UHFFFAOYSA-N 0.000 description 1
- PNIFOHGQPKXLJE-SDQBBNPISA-N maritimetin Chemical compound C1=C(O)C(O)=CC=C1\C=C/1C(=O)C(C=CC(O)=C2O)=C2O\1 PNIFOHGQPKXLJE-SDQBBNPISA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- VWDLOXMZIGUBKM-AUGXRQBFSA-N stigmasterol 3-O-beta-D-glucoside Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWDLOXMZIGUBKM-AUGXRQBFSA-N 0.000 description 1
- VWDLOXMZIGUBKM-PPUGUTTCSA-N stigmasterol 3-O-beta-D-glucoside Natural products CC[C@H](C=C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)C(C)C VWDLOXMZIGUBKM-PPUGUTTCSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to the use of alcohol extract of sponish needles herb in preparing medicine for preventing and treating non-alcoholic fatty liver. The alcohol extract of sponish needles herb is the effective part extracted from sponish needles herb, and animal experiments show that alcohol extract of sponish needles herb can lower the lipid of high fat diet resulted in model animal and drug poisoning model animal and protect liver cell of the fatty liver animal. The medicine of alcohol extract of sponish needles herb for preventing and treating non-alcoholic fatty liver is orally taken, and has taking convenience and less toxic side effect.
Description
Technical field
The present invention relates to the new purposes of alcohol extract of spanishneedles herb, relate in particular to the purposes of alcohol extract of spanishneedles herb in pharmaceutical field, the definite purposes of saying so and preventing and treating in the non-alcoholic fatty liver disease medicine preparing.
Background technology
Herba Bidentis Bipinnatae has another name called Herba Bidentis Bipinnatae, terrible wooden fork grass, little Bidens bipinnata, sticking body grass etc., and its medicinal history is long, and the beginning is stated from Tang's CHEN Zang-Qi supplement to the Herbal, meaning: " terrible hairpin grass, bitter in the mouth is flat, nontoxic, main Serpentis and Aranea sting, broken Fu of pestle it, also pestle strand juice clothes.There is fork at Radix Rehmanniae side, and square-stem, son are made the hairpin foot, people such as clothing pin, and what exhaled in the north is Bidens bipinnata.But " all medications of Herba Bidentis Bipinnatae class medical material herb, bitter in the mouth is flat and nontoxic, has heat-clearing and toxic substances removing, and effects such as dissipating blood stasis for subsidence of swelling cure mainly malaria, diarrhoea, dysentery, hepatitis, acute nephritis, stomachache, dysphagic, acute appendicitis, laryngopharynx swelling and pain, traumatic injury, snake bite and insect sting etc.In order better to be familiar with and to understand this natural resources, better develop and use, existing that the research and development review of Present Situation of Herba Bidentis Bipinnatae is as follows.
Herba Bidentis Bipinnatae is that Compositae (Compositae) tubular flower subfamily Bidens (Bidens L.) plant is an annual herb, its herb resource is very abundant, mainly be distributed in ground such as China northeast, Hebei, Shandong, Shanxi, Henan, Jiangsu, Yunnan, Sichuan, Guangdong and Guangxi Provinces, be born in waterside, riverbank, wetland, wasteland and hillside etc. and locate, very easily gather.
The chemical constituent of Herba Bidentis Bipinnatae:
The contained chemical constituent kind of Herba Bidentis Bipinnatae is more, and bibliographical information once separated from this plant and obtains volatile oil, sterol, chalcone derivative, aurones, polyacetylene class etc., and its active component is based on polyacetylene class and flavones ingredient.Isolated multiple polyacetylene constituents.The n-butyl alcohol of ethanol extraction partly identifies 4 flavone components, is hyperin (hyperoside), okanin (okanin), isookanin-7-O-glycoside and maritimetin (maritimein).In each position of Herba Bidentis Bipinnatae there be than big-difference flavones ingredient, at flowering fruit bearing stage, and general flavone content higher (being respectively 6.67% and 6.68%) in leaf and the inflorescence, content lower (0.89%) in the stem branch.In the leaf isolation identification 21 kinds of volatile ingredients, be mainly fatty alkane and fatty acid, contain a spot of aldehyde, ketone alkene, nitrile, amine and furans composition in addition; Wherein fats compound accounts for significant proportion.Isolated 4 kinds of liposoluble ingredients through physics and chemistry test and spectrum analysis, are accredited as salicylic acid, protocatechuic acid, gallic acid, fatty acid compound respectively.Also have steroid compound such as spinach sterol, daucosterol, sitosterol, stigmasterol-3-O-β-D-glucoside.
Herba Bidentis Bipinnatae contains rich in amino acid, as 17 seed amino acids such as aspartic acid, threonine, serine, glutamic acid, alanine, valine, isoleucine, proline, tyrosine, lysines, wherein 8 kinds is essential amino acid, gross protein 157.89g/kg, total free amino acid content reaches 139.89g/kg, TEAA 57.09g/kg.Amino acid contained and the traditional rare medicinal herbs Cordyceps hawkesii Gary of Herba Bidentis Bipinnatae, Cordyceps are compared, many cystine on kind, and proline, glutamic acid are higher than both on content, and other amino acid contents are suitable
Also contain 11 kinds of micro elements needed by human in addition in the Herba Bidentis Bipinnatae, measurement result shows, Mg content is the highest, P, Fe, Ca content are higher, Cu, Zn take second place, Mn, Co, Ni, Mo, Cr content are minimum, contain abundant P in the Herba Bidentis Bipinnatae, are that it regulates immanent cause that nerve, hypnosis, calmness etc. act on.
Vitamin also has distribution in Herba Bidentis Bipinnatae, as vitamin B
1, vitamin B
2, beta-carotene.
The Herba Bidentis Bipinnatae herb resource is abundant, and medicinal history is long, and Radix Codonopsis Cardiophyllae's title is arranged in folk remedy.Its biological activity is various, and action temperature and lasting, has higher medical value, especially digestive system, central nervous system and cardiovascular system is shown stronger pharmacological action.In recent years the Herba Bidentis Bipinnatae medical material some developments and utilizations have been carried out, domestic Herba Bidentis Bipinnatae product has the year of a pleasing sheet, Herba Bidentis Bipinnatae oral liquid, Herba Bidentis Bipinnatae health instant powder etc. at present, but also only limit to prevent and treat cardiovascular disease such as hypertension, yet there are no alcohol extract of spanishneedles herb at the report aspect the preparation control non-alcoholic fatty liver disease medicine.
Summary of the invention
The new purposes that the purpose of this invention is to provide alcohol extract of spanishneedles herb, i.e. new application in pharmacy.
In fact, the invention provides the application of alcohol extract of spanishneedles herb in the medicine of preparation prevention or treatment non-alcoholic fatty liver disease.
In recent years, along with improving constantly of China people material life, the sickness rate of non-alcoholic fatty liver disease (NASH) rises year by year, surpasses viral hepatitis and becomes first hepatopathy at certain areas non-alcoholic fatty liver disease NASH.Non-alcoholic fatty liver disease NASH is that the class liver histological similar to alcoholic liver disease changes, but not having excessive history of drinking history (takes in the clinical pathology syndrome of ethanol<40g/d), is primary in metabolism disorders such as the obesity relevant with insulin resistant, type ii diabetes, hyperlipemia, hypertension usually.Previously think, fatty liver is a benign lesion, can not develop into hepatic fibrosis, liver cirrhosis, but a large amount of clinical liver biopsies studies confirm that, non-alcoholic fatty liver disease NASH about 40%-50% on the basis of fat hepatitis can develop into hepatic fibrosis, 15%-20% can develop into liver cirrhosis, even can cause the generation of hepatocarcinoma.Therefore the positive control of NASH can stop the progress of chronic hepatopathy, improves NASH patient's prognosis.
The measure that is used for the treatment of at present non-alcoholic fatty liver disease NASH clinically mainly comprises (1) removal cause of disease and inducement; (2) keep on a diet; (3) exercise therapy; (4) pharmaceutical intervention etc.The drug development for the treatment of NASH in recent years is very fast, and its main medicine has:
A, at improving insulin resistant, increase the medicine of insulin sensitivity.As the two croaks of diformazan, can obviously improve patient's carbohydrate tolerance and hyperinsulinemia, reduce blood plasma free fatty acid and plasma triglyceride level.Its main adverse reaction is a symptom of digestive tract, has the inclination, the gerontal patient of renal dysfunction has the danger that lactic acidosis takes place, and does not still have the randomized controlled experimentation at present and confirms that this medicine can be used safely in to treat non-alcoholic fatty liver disease.
B, inhibition peroxidation medicine.As vitamins, main prevent that by suppressing the formation of peroxylradicals cell is impaired, but vitamin A, E all belong to fatsoluble vitamin, heavy dose of replenishing easily produces accumulate poisoning and increases the weight of hepatic injury.
C, at the medicine of hyperlipemia, carry out metabolism but many hypolipidemics can promote blood fat more to concentrate on liver, may promote lipid accumulating in liver on the contrary, and further damage liver function.
D, ursodesoxycholic acid can reduce non-alcoholic fatty liver disease patients serum enzyme level, but can not change the liver fat deposition.
Generally speaking, though the medicine of large quantities of treatment non-alcoholic fatty liver diseases is arranged at present, still lack the medicine safe and effective, that effect is sure for clinical use.Therefore, actively seek have protect the liver, blood fat reducing, lipotropic medicine be very important, and the advantage of performance Chinese medicine is particularly important.The great advantage of the chronic fatty liver illness of Chinese medicine is that side effect is little, and in treatment, its disease that is associated is had certain therapeutical effect as obesity, hyperlipemia, hypertension, diabetes etc., so have wide application and DEVELOPMENT PROSPECT.
According to Traditional Chinese medical theory, the differential diagnosis in tcm of most of chronic hepatitis patients diagnosis pattern of syndrome is syndrome of stagnation of liver qi and spleen deficiency and congestion resistance network card, and corresponding treatment should be benefiting QI and nourishing blood, blood circulation promoting and blood stasis dispelling, the liver soothing and the spleen invigorating.The present invention follows this Therapeutic Principle, based on the long-term treatment experience, find that Herba Bidentis Bipinnatae has heat-clearing and toxic substances removing, effects such as dissipating blood stasis for subsidence of swelling, not only have effects such as resisting hypertension, blood sugar lowering, and non-alcoholic fatty liver disease also had good therapeutical effect, for the active drug that it is developed to the hepatopathy effect provides the foundation that is of great rarity.We extract its effective site, confirm the effect that it has significant control non-alcoholic fatty liver disease by zoopery.
In order to understand essence of the present invention better, will its application in control non-alcoholic fatty liver disease medicine be described with the pharmacological evaluation and the result of alcohol extract of spanishneedles herb below.
The test of alcohol extract of spanishneedles herb control non-alcoholic fatty liver disease is as follows:
(1) preparation of alcohol extract of spanishneedles herb
Get the Herba Bidentis Bipinnatae crude drug and pulverize, the alcohol reflux of 40-80% 2-3 time, extracting solution merges, and reclaims ethanol, and concentrating under reduced pressure gets extractum.Extractum is water-soluble, leaves standstill, filter, and resin column on the clear liquor, 40-95% ethanol elution part is collected in the washing back, reclaims ethanol, and concentrating under reduced pressure is drying to obtain alcohol extract of spanishneedles herb.This alcohol extract is the yellow green powder, has fragranced, easily deliquescence; Its main component is a total flavones, and content is 20-60%.This alcohol extract can add corresponding adjuvant, makes tablet, capsule, slow releasing tablet, drop pill, electuary, microgranule, and is further purified and makes injection.
(2) experiment
1. alcohol extract of spanishneedles herb causes the protective effect of chmice acute chemical liver injury to carbon tetrachloride
(1) material and reagent: alcohol extract of spanishneedles herb; 0.1%CCl
4Bifendate; ALT, the AST test kit: biotech company is built up in Nanjing; 60 of Male Kunming strain mice, body weight 18-22g is provided by Medical University Of Anhui zoopery center.
(2) method: 60 of normal mouses divide 6 groups at random, gastric infusion (alcohol extract of spanishneedles herb 80mg/kg, 160mg/kg, 320mg/kg, positive drug control group bifendate 100mg/kg) or equal-volume normal saline (normal control, model), every day 2 times, continuous 7d, 2h after the last administration, normal control group ip10ml/kg Oleum Arachidis hypogaeae semen, all the other 5 groups of equal ip0.1%CCl
410ml/kg from mice posterior orbit vein treating the preponderant disease instead of the secondary disease blood, measures Serum ALT behind the fasting 16h, the AST activity, and get the same position of liver lobus sinister, fixing, do pathological section, carry out hepatic pathology histology HE chromoscopy, the result with hepatic pathology degree of injury scoring under the light microscopic and pathology photo as standard.
Liver tissue lesions's grading method: light microscopic is checked down, is divided into 5 grades by the hepatic necrosis degree:
0 grade, normal or liver has slight degeneration, and hepatocyte does not have necrosis;
The I level, spotty necrosis, necrosis accounts for lobules of liver<1/4;
The II level, the necrosis of some kitchen range shape, necrosis accounts for lobules of liver 1/4-1/3;
The III level, the necrosis of kitchen range shape, necrosis accounts for lobules of liver<1/2;
The IV level, lamellar necrosis, necrosis account for lobules of liver>1/2
(3) result: table 1 is the result show, CCl
4ALT, AST activity in the remarkable rising mice serum, and alcohol extract of spanishneedles herb significantly reduces CCl
4Cause ALT too high in the acute chemical hepatic injury mice serum, AST activity.
Table 1 Sticktight general flavone is to the influence of ALT, AST in the mice serum (n=10, x ± s)
Group | Dosage/mgkg -1 | ALT/U·L -1 | AST/U·L -1 |
Matched group model group positive drug alcohol extract of spanishneedles herb | - - 100 320 160 80 | 46.13±6.76 144.73±12.11** 46.61±12.51## 57.80±30.22## 75.96±32.58## 105.72±30.00## | 45.21±16.12 93.24±36.11** 62.05±14.09 54.79±14.82## 37.96±14.10## 79.85±26.75 |
* p<0.01 is compared with matched group; ##p<0.01 is compared with model group
Table 2 result shows that necrosis in different degree appears in the visible inflammatory cell infiltration of model group hepatic tissue.Alcohol extract of spanishneedles herb can obviously alleviate liver inflammatory cell infiltration and necrosis.
Table 2 alcohol extract of spanishneedles herb is to CCl
4Cause the influence of acute chemical hepatic injury mice histopathology
Group | Dosage mg/kg | Classification | ||||
0 | I | II | III | IV | ||
Normal group | - | 10 | 0 | 0 | 0 | 0 |
Model group | - | 3 | 4 | 2 | 2 | 0 |
The positive drug group | 100 | 11 | 0 | 0 | 0 | 0 |
Alcohol extract of spanishneedles herb | 320 | 10 | 2 | 0 | 0 | 0 |
160 | 12 | 0 | 0 | 0 | 0 | |
80 | 0 | 2 | 3 | 3 | 4 |
1, alcohol extract of spanishneedles herb is to the therapeutical effect of serum lipids in rats fatty liver
(1) material and reagent:
66 of SD rats, male and female half and half, body weight 180-200g is provided by Medical University Of Anhui's Experimental Animal Center; Alcohol extract of spanishneedles herb; DONGBAO GANTAI PIAN (Shanghai nine good fortune pharmaceutcal corporation, Ltds); TG, TC, HDL-C measure test kit available from Beijing Fu Rui bio-engineering corporation; ALT, MDA, SOD, GLU, FFA measure test kit and build up bio-engineering research institute available from Nanjing;
The preparation of lipomul: get in the beaker that Adeps Sus domestica 25g adds 200mL, heated and stirred adds the 10g cholesterol, dissolves, and it is excellent to add 1g third match again, fully stirs evenly, and adds the 25mL Tween 80 then, makes oil phase.Add 30mL distilled water and 1-2 propylene glycol 20mL simultaneously in another beaker, heating adds the 2g NaTDC then, fully stirs up to dissolving fully, makes water.Then water is added oil phase, fully mixing is promptly made lipomul, uses preceding 37 ℃ of heating in water bath.
(2) method:
The SD rat after one week, is divided into 2 groups at laboratory rearing at random: normal group (n=12), lipomul group (n=54).The lipomul group gives lipomul filling stomach every day, and normal group gives equal-volume CMC-Na simultaneously.Behind the 3W, hematometry TG is got in docking, the lipomul group get 50 by blood lipid level be divided into DONGBAO GANTAI group, alcohol extract of spanishneedles herb (320,160,80mgkg
-1) group, model group, to remove matched group and model group and give equal-volume CMC-Na, other each group gives relative medicine respectively.3 week of administration, animal was put to death in the back, and taking-up serum and liver are measured serum TG, TC, HDL-C, ALT, MDA, SOD, FFA and liver homogenate TG, MDA, SOD.
(3) result
Make when touching for 3 weeks, lipomul group blood fat significantly raises.Make as seen from Table 3 touch 6 when week the model group serum TC and TG all be significantly higher than matched group; Compare with model group, DONGBAO GANTAI group and Sticktight general flavone group serum TG obviously reduce, and Serum HDL-C raises.As seen, compare with matched group in the variation of table 4 Serum ALT, SOD, MDA, FFA, model group ALT, FFA, MDA obviously raise; Compare with model group, east protects the liver safe group and alcohol extract of spanishneedles herb group FFA, MDA, ALT obviously descend.Compare with matched group in the visible liver homogenate of table 5, model group TG, MDA significantly raise, and SOD then reduces; Compare with model group, DONGBAO GANTAI group and alcohol extract of spanishneedles herb group can reduce TG, MDA, and the alcohol extract of spanishneedles herb group can also increased SOD.Show that thus alcohol extract of spanishneedles herb has the effect of tangible Chinese People's Anti-Japanese Military and Political College Mus hyperlipemia-fatty liver.
Table 3 the 6th respectively organize during week serum lipids change (x ± s, n=10)
Group | Dosage/mgkg -1 | TG/mmol·l -1 | TC/mmol·l -1 | HDL-C/mmol·l -1 |
Matched group model group DONGBAO GANTAI alcohol extract of spanishneedles herb | - - 120 320 160 80 | 0.39±0.09 0.54±0.10** 0.47±0.08# 0.43±0.08# 0.46±0.10# 0.54±0.10 | 1.45±0.17 2.14±0.28** 2.23±0.50 2.13±0.36 2.25±0.30 2.26±0.43 | 1.05±1.45## 0.53±0.1 0.67±0.06# 0.66±0.10# 0.65±0.06# 0.64±0.08# |
* p<0.05, * * p<0.01 is compared with matched group; #p<0.05, ##p<0.01 is compared with model group
Table 4 respectively organize Serum ALT, MDA, SOD, FFA variation (x ± s, n=10)
Group | Dosage/mgkg -1 | FFA/μmol·ml -1 | ALT/U·l -1 | MDA/n mol·ml -1 | S0D/U·ml -1 |
The alcohol extraction of matched group model group DONGBAO GANTAI Herba Bidentis Bipinnatae | - - 120 320 160 80 | 430.69±134.92 758.58±103.54** 565.23±99.96## 504.64±108.64## 616.65±128.05# 744.85±108.96 | 13.62±8.40 44.95±21.10** 24.57±15.28# 23.81±13.28# 24.61±8.99# 34.90±16.68 | 15.52±2.02 18.69±3.37* 16.12±1.67# 15.23±2.61# 16.05±2.41# 18.26±3.51 | 189.09±23.72 172.80±24.19 190.22±17.85 191.34±18.80 180.67±19.58 178.31±17.54 |
* p<0.05, * * p<0.01 is compared with matched group; #p<0.05, ##p<0.01 is compared with model group
Table 5 respectively organize TG in the liver homogenate, MDA, SOD variation (x ± s, n=10)
Group | Dosage/mgkg -1 | TG mmol·l -1 | MDAnmol·mg - | SODU·mg -1 |
Matched group model group DONGBAO GANTAI alcohol extract of spanishneedles herb | - - 120 320 160 80 | 0.47±0.07 1.04±0.12** 0.72±0.10## 0.62±0.11## 0.90±0.08## 0.93±0.12# | 0.25±0.07 0.42±0.07** 0.34±0.10# 0.32±0.09## 0.34±0.09# 0.33±0.08# | 7.57±1.02 6.46±0.71* 7.12±0.76 7.41±1.21# 7.27±1.59 6.30±0.66 |
* p<0.05, * * p<0.01 is compared with matched group; #p<0.05, ##p<0.01 is compared with model group
2, alcohol extract of spanishneedles herb causes the influence of rat fat liver to ethionine
(1) method: get 66 of SD rats, male and female half and half, body weight is 180-200g, is divided into 6 groups, promptly blank group and model group (irritate stomach give equal-volume CMC-Na), DONGBAO GANTAI group, alcohol extract of spanishneedles herb (320,160,80mgkg
-1).From testing the 1st day, every day gastric infusion once, successive administration 3 days is tested and was risen in the 4th day, except that the blank group, irritates stomach by the 0.25g/kg body weight respectively for all the other 5 groups and gives ethionine once, subsequently, every 12h is administered once by preceding method, totally 4 times.Give 48h behind the ethionine, get hematometry TC, TG and liver homogenate TC, TG.
(2) result:
Table 6 alcohol extract of spanishneedles herb causes the influence (x ± s) of rat fat liver to ethionine
Group | Dosage/mgkg -1 | Blood TCmmol/l | Blood TGmmol/l | Liver TCmmol/l | Liver TGmmol/l |
Matched group model group DONGBAO GANTAI Sticktight general flavone | - - 120 320 160 80 | 0.64±0.12** 0.91±0.16 0.58±0.11** 0.59±0.15** 0.61±0.12** 0.63±0.11** | 0.63±0.11* 0.83±0.21 0.60±0.12* 0.62±0.13* 0.64±0.14* 0.75±0.12 | 0.50±0.13** 0.67±0.09 0.46±0.16** 0.42±0.08** 0.48±0.09** 0.53±0.12* | 0.44±0.09** 0.65±0.12 0.48±0.13* 0.44±0.131** 0.47±0.15* 0.49±0.16* |
* p<0.05, * * p<0.01 is compared with model group
By the visible alcohol extract of spanishneedles herb of table 6 result obviously hypercholesterolemia reducing and content of triglyceride, has the effect that certain anti-ethionine causes fatty liver.
Above-mentioned experimental result shows that the present invention has the advantage of several aspects:
1, alcohol extract of spanishneedles herb of the present invention is the effective ingredient that extracts from the Chinese crude drug Herba Bidentis Bipinnatae, can obviously reduce the lipid in high fat diet fatty liver model and the drug intoxication fatty liver model, and the hepatocyte in the fatty liver model is had protective effect; Excavate the new prospect in medicine of alcohol extract of spanishneedles herb, opened up a new medicinal field;
2, alcohol extract of spanishneedles herb of the present invention adopts oral administration, taking convenience, and toxic and side effects is little, takes medicine for a long time and does not have harm;
3, the former medicine resource of alcohol extract of spanishneedles herb of the present invention is very abundant, has good society and economic benefit;
4, alcohol extract of spanishneedles herb of the present invention is applicable to non-alcoholic fatty liver disease, acts on a plurality of links, determined curative effect;
5, the present invention provides strong basis for Herba Bidentis Bipinnatae being developed further into new drug.
The specific embodiment
Below in conjunction with embodiment the present invention is done to describe further.
Embodiment 1:
Take by weighing Herba Bidentis Bipinnatae crude drug 10kg, pulverize the back and add 80% ethanol 100L, hot reflux is extracted 2 times, each 1h, and merge extractive liquid, reclaims ethanol, and concentrating under reduced pressure gets extractum.Extractum is water-soluble, leaves standstill, filter, and macroporous resin column on the clear liquor, 80% ethanol elution part is collected in the washing back.Reclaim ethanol, concentrating under reduced pressure is drying to obtain alcohol extract of spanishneedles herb.This alcohol extract is the yellow green powder, has fragranced, easily deliquescence; Its main component is a total flavones, and content is 20-60%.This alcohol extract can add corresponding adjuvant, makes tablet, capsule, slow releasing tablet, drop pill, electuary, microgranule, and is further purified and makes injection.
The clinical recommended dose of alcohol extract of spanishneedles herb: 300-1200mg/ days, oral, three times on the one.
Claims (1)
1, the application of alcohol extract of spanishneedles herb in preparation control non-alcoholic fatty liver disease medicine is characterized in that: the application of alcohol extract of spanishneedles herb in preparation control non-alcoholic fatty liver disease medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510097344 CN100486601C (en) | 2005-12-31 | 2005-12-31 | Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510097344 CN100486601C (en) | 2005-12-31 | 2005-12-31 | Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1887303A true CN1887303A (en) | 2007-01-03 |
CN100486601C CN100486601C (en) | 2009-05-13 |
Family
ID=37576583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510097344 Expired - Fee Related CN100486601C (en) | 2005-12-31 | 2005-12-31 | Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100486601C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103416352A (en) * | 2012-05-22 | 2013-12-04 | 浙江中医药大学 | Animal model of hypertension comprehensively caused by high-salt, high-sugar and high-fat diet |
CN103416347A (en) * | 2012-05-22 | 2013-12-04 | 浙江中医药大学 | Lifestyle hypertension animal model caused by drinking and high-sugar high-fat diet |
-
2005
- 2005-12-31 CN CN 200510097344 patent/CN100486601C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103416352A (en) * | 2012-05-22 | 2013-12-04 | 浙江中医药大学 | Animal model of hypertension comprehensively caused by high-salt, high-sugar and high-fat diet |
CN103416347A (en) * | 2012-05-22 | 2013-12-04 | 浙江中医药大学 | Lifestyle hypertension animal model caused by drinking and high-sugar high-fat diet |
Also Published As
Publication number | Publication date |
---|---|
CN100486601C (en) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
CN101357219B (en) | Medicine for treating chronic hepatitis B | |
Chen et al. | The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility | |
CN1965885B (en) | Application of total flavones of chickpea in preparation of medicament for treating diabetes | |
CN102233119A (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
CN1840166A (en) | Modern Chinese medicinal oral liquid of 'Wen Dan Tang' and preparation method thereof | |
CN101250207A (en) | Canton love-pea vine total flavone c-glycosides effective part, preparation method and use thereof | |
CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
CN102362971A (en) | Traditional Chinese medicine for treating coronary disease, preparation method of active chemical ingredients thereof and preparation | |
CN100486601C (en) | Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver | |
CN104337884A (en) | Medicine composition for preventing and/or treating diabetes and complication of diabetes | |
CN100486599C (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating viral hepatitis | |
CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
CN102293796B (en) | Active part of lysimachia trientaloides Hemsl., and extraction method and application of active part | |
CN100486600C (en) | Application of spanishneedles herb flavonid in preparing medicine for preventing and treating liver fibrosis | |
CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
CN101632829B (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
CN100515436C (en) | Application of total flavone from sticktight in preparing medicine for treating hepatic fibrosis in type of blood fluke | |
CN1087627C (en) | Medicament for treating diabetes and its preparation method | |
CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
CN104547026A (en) | Preparation method and application of salvia miltiorrhiza leave and panax pseudo-ginseng extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090513 Termination date: 20161231 |